The effects of levosimendan and glibenclamide on circulatory and metabolic variables in a canine model of acute hypoxia
Open Access
- 5 March 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in Intensive Care Medicine
- Vol. 37 (4), 701-710
- https://doi.org/10.1007/s00134-011-2144-1
Abstract
Purpose To study the effects of pretreatment with levosimendan (LEVO, a Ca2+-sensitizer and K +ATP channel opener) and/or the K +ATP channel antagonist glibenclamide (GLIB) on systemic hemodynamics, metabolism, and regional gastromucosal oxygenation during hypoxic hypoxemia. Methods Chronically instrumented, healthy dogs (24–32 kg, n = 6 per group, randomized cross-over design) were repeatedly sedated, mechanically ventilated (FiO2 ~0.3) and subjected to the following interventions: no pretreatment, LEVO pretreatment, GLIB pretreatment, or combined LEVO + GLIB pretreatment, each followed by hypoxic hypoxemia (FiO2 ~0.1). We measured cardiac output (CO, ultrasonic flow probes), oxygen consumption (VO2, indirect calorimetry), and gastromucosal microvascular hemoglobin oxygenation (μHbO2, spectrophotometry). Statistics: data are presented as mean ± SEM and compared by one-way ANOVA (direct drug effects within group) and two-way ANOVA (between all hypoxic conditions) both with Bonferroni corrections; p < 0.05. Results In LEVO-pretreated hypoxemia, CO was significantly higher compared to unpretreated hypoxemia. The increased CO was neither associated with an increased VO2 nor with markers of aggravated anaerobiosis (pH, BE, lactate). In addition, LEVO pretreatment did not further compromise gastromucosal μHbO2 in hypoxemia. After combined LEVO + GLIB pretreatment, systemic effects of GLIB were apparent, however, CO was significantly higher than during unpretreated and GLIB-pretreated hypoxemia, but equal to LEVO-pretreated hypoxemia, indicating that GLIB did not prevent the increased CO in LEVO-pretreated hypoxia. Conclusions LEVO pretreatment resulted in improved systemic circulation (CO) during hypoxemia without fueling systemic VO2, without aggravating systemic anaerobiosis markers, and without further compromising microvascular gastromucosal oxygenation. Thus, LEVO pretreatment may be an option to support the systemic circulation during hypoxia.This publication has 48 references indexed in Scilit:
- Levosimendan for the treatment of acute severe heart failure: A meta-analysis of randomised controlled trialsInternational Journal of Cardiology, 2010
- Effect of tidal volume, sampling duration, and cardiac contractility on pulse pressure and stroke volume variation during positive-pressure ventilationCritical Care Medicine, 2008
- Inhibition of potassium channels in critical illnessCurrent Opinion in Anaesthesiology, 2008
- Mitochondrial contribution to the molecular mechanism of heart acclimatization to chronic hypoxia: role of nitric oxideFrontiers in Bioscience-Landmark, 2007
- Vasodilation from Sufentanil in HumansAnesthesia & Analgesia, 2005
- Closed system anaesthesia in dogs using liquid sevoflurane injection; evaluation of the square-root-of-time model and the influence of CO2 absorbentVeterinary Anaesthesia and Analgesia, 2005
- Continuous positive airway pressure, shock therapy, and gastric mucosal oxygenation *Critical Care Medicine, 2003
- O2 Delivery and the Venous PO2 -O2 Uptake Relationship in Pump-Perfused Canine MuscleExperimental Physiology, 2002
- Bronchoscopy with bronchoalveolar lavage via the laryngeal mask airway in high-risk hypoxemic immunosuppressed patientsCritical Care Medicine, 2001
- Levosimendan, a New Positive Inotropic Drug, Decreases Myocardial Infarct Size via Activation of KATP ChannelsAnesthesia & Analgesia, 2000